A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

Although the targets of biomanufacturing have evolved from therapeutic proteins to “advanced therapies” and now to gene therapies, the issues and solutions remain the same. The production of safe, ...

Effective process development for viral vector-based medicines is paramount for optimized process efficiency, robustness, scalability, and product quality. Well-designed processes streamline ...

Austin, Texas, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Viral Vectors and Plasmid DNA Manufacturing Market Size & Growth Analysis: According to SNS Insider, the Viral Vectors and Plasmid DNA Manufacturing ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...

Cell and gene therapies are changing lives. They engineer patients’ cells or DNA to create personalized therapies, unlocking long-lasting or even curative treatments for diseases with high unmet needs ...

James Miskin brings 25 years of cell and gene therapy experience to an advisory role focused on further unlocking ViroCell’s potential LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell ...

In a bid to streamline viral vector manufacturing, Thermo Fisher is charting another round of layoffs this year—and mothballing a Massachusetts factory along the way. Thermo Fisher is cutting a total ...

Chimeric antigen receptor T-cell (CAR-T) therapies have emerged as a revolutionary approach in the field of hematological malignancies, offering unprecedented clinical efficacy when patients have ...